Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma.
Nivolumab plus ipilimumab demonstrated improvement in overall survival for patients with metastatic uveal melanoma.
The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma.
First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma.
In a 6.5-year update of CheckMate-067, durable improvements in overall survival, progression-free survival, and objective response rate were observed with nivolumab plus ipilimumab over nivolumab alone as first-line therapy in patients with advanced melanoma, with no new safety signals.
Neoadjuvant and adjuvant treatment with nivolumab plus relatlimab for resectable stage III melanoma achieved high pathologic complete response and major pathologic response rates.
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma.
Treatment for NSCLC using the combination of tiragolumab plus atezolizumab was more effective than treatment with placebo plus atezolizumab.
Durvalumab plus either oleclumab or monalizumab improved overall response rate, progression-free survival, and 10-month progression-free survival in locally advanced, unresectable, stage III NSCLC.
The phase 3 CheckMate-743 trial demonstrated survival improvement over 3 years with first-line nivolumab plus ipilimumab for patients with unresectable malignant pleural mesothelioma.
Page 1 of 22
Results 1 - 10 of 219
© Amplity Health. All rights reserved.